Abstract
Over 30% of gastric cancers in China are at stage IV disease at the time of diagnosis which is incurable or unresectable. Reduction surgery refers to non-curative gastrectomy for reducing tumor burden in the absence of severe symptoms. The benefit of reduction gastrectomy for these patients is controversial. Most of the retrospective data support its necessity. However, the results of the Japanese REGATTA study showed that reduction gastrectomy could not bring any survival benefit to patients compared with chemotherapy alone, so the guideline of the Japanese Society of Gastric Cancer is strongly against reduction gastrectomy. Although the design of the REGATTA study is not perfect and the conclusion is challenged, it provides the highest level of evidence. Surgeons should abstain from prophylactic reduction gastrectomy in clinical setting. The strategy should be decided by MDT discussion.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
